ArticleScientific reports2025
Berberine treatment inhibits ferroptosis in NIT-1 murine pancreatic cell line via inhibiting OGT expression levels.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- ComTarget: Small-Molecule Target Prediction with Combinatorial Modeling.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Berberine-induced ferroptosis as a novel anti-cancer strategy: Molecular, epigenetic and translational perspectives.EXCLI journal · 2026Review
- Berberine alleviates pyroptosis of retinal ganglion cells in diabetic retinopathy by regulating AKT1, JUN, and STAT3.Ibrain · 2026Article
- Integrating clinical evidence with natural product therapies for elderly-onset type 2 diabetes.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, the prevalence of diabetes mellitus (DM) in the world continues to rise, which has seriously threatened human health. Enhanced pancreatic β-cell death is one of the important factors in the pathogenesis of type 1 diabetes mellitus (T1DM). Berberine, an alkaloid, plays a series of pharmacological functions in many disease. The purpose of this study was to explore the specific mechanisms of berberine in the high glucose (HG) stimulated pancreatic β-cell. The 30 mM D-glucose stimulated mouse pancreatic β cells (NIT-1) was used to estabilish T1DM model in vitro. Then the cell viability was detected by CCK-8 assay. The lactic dehydrogenase (LDH), reactive oxygen species (ROS), Iron, malondialdehyde (MDA), glutathione (GSH), and glutathione peroxidase 4 (GPX4) levels were determined by corresponding kits. The cell death was evaluated by PI staining. Western blot was performed to measure the O-linked N-acetylglucosamine (O-GlcNAc) and O-GlcNAc transferase (OGT) protein levels. The results showed that berberine treatment significantly increased the cell viability, GPX4 activity and GSH levels, and decreased the ROS, Iron, MDA levels and PI positive cells in the HG stimulated NIT-1 cells. Additionally, the molecular docking analysis showed that berberine could bind to OGT. Berberine treatment significantly decreased the global O-GlcNAc levels and OGT protein expression in the HG stimulated NIT-1 cells. Furthermore, OGT overexpression reversed the role of berberine in the HG stimulated NIT-1 cells. This study demonstrated that berberine treatment inhibited the ferroptosis of pancreatic β-cell under high-glucose condition via decreasing the OGT expressions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.